Regular Article
Induction of Heme Oxygenase-1 Can Act Protectively against Cardiac Ischemia/Reperfusion in Vivo

https://doi.org/10.1006/bbrc.2000.3973Get rights and content

Abstract

Enhanced production of reactive oxygen species plays a role in myocardial injury following ischemia/reperfusion. Heme oxygenase-1 (HO-1) is a heme-catabolizing enzyme that is induced by and acts against oxidant-induced tissue injury. We examined whether HO-1 expression was regulated following ischemia and reperfusion in the rat heart. HO-1 expression increased as early as 24 h after reperfusion. Strong HO-1 expression was seen in monocytes/macrophages and myofibroblasts. Next, we examined whether the induction of HO-1 could ameliorate cardiac injury following ischemia/reperfusion. Intraperitoneal hemin injection (30 mg/kg/day) for 2 days prior to the operation resulted in an about 2.8-fold increase in HO-1 expression in the rat heart. Hemin treatment significantly decreased infarct area (6 ± 2%) compared to the control (21 ± 2%), which was reversed by the coadministration of an HO inhibitor in a dose-dependent manner. Our data suggest that induction of HO-1 can reduce the cardiac injury in vivo following ischemia/reperfusion.

References (25)

  • L. Tacchini et al.

    Expression of HSP 70, immediate-early response and heme oxygenase genes in ischemic-reperfused rat liver

    Lab. Invest.

    (1993)
  • M.D. Maines et al.

    Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfusion: Possible role of heme as both promotor of tissue damage and regulator of HSP32

    J. Pharmacol. Exp. Ther.

    (1993)
  • Cited by (113)

    • Study on the detoxification mechanisms to 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinato iron(III) chloride (FeTPPS), an efficient pro-oxidant of heme water-soluble analogue

      2018, Journal of Inorganic Biochemistry
      Citation Excerpt :

      Upregulation of HO-1 represents one of the most critical cytoprotective mechanisms in maintaining antioxidant/oxidant homeostasis. Many studies even reported the upregulation of HO-1 induced by heme make heme as an indirect anti-oxidant at nontoxic concentrations and plays a key role in preventing injury caused by many diseases [34–45]. It suggests that the deleterious effects of heme exhibit only at high concentration when the protective ability of heme detoxification is overwhelmed.

    • Systemic hemin therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage

      2014, Neurobiology of Disease
      Citation Excerpt :

      Delaying the first hemin injection until 3 h after ICH induction did not significantly diminish this effect. Although a hemin dose approximating 26 mg/kg hemin has frequently been employed in animal studies (Attuwaybi et al., 2004; Belcher et al., 2006; Hangaishi et al., 2000; Takizawa et al., 1998), the dose of ferric heme that is currently approved for human use is 1–4 mg/kg administered daily for 3–14 days, with a recommended daily dose of 3–4 mg/kg (Anderson et al., 2005) and a maximum of 6 mg/kg/24 h. To further test the translational relevance of hemin therapy, additional experiments were conducted using a similar dose (4 mg/kg). Evans blue leakage into the striatal parenchyma in mice treated with this lower hemin dose was somewhat greater than at the higher dose but was about half of that observed in vehicle-treated mice (Fig. 3).

    View all citing articles on Scopus
    1

    To whom correspondence should be addressed at Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. Fax: 81-3-3974-2236. E-mail: [email protected].

    View full text